To determine the effect of combination therapy of EphA2 and Wee1 inhibitors (ALW and MK1775, respectively), cancer cells were treated with either each single drug or both in combination for a period of 72 h, followed by cell viability analysis using an MTT assay. Here, EPHA2 is linked to cancer.